Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3 β activation.

In this study, we found that the proliferation of MG-63 cells was significantly decreased after treatment with 25, 50, 100, or 200 μM ZOL for 48 and 72 h compared to that of untreated control cells. The expression levels of p-AKT/AKT and p-GSK-3β/GSK-3β in MG-63 cells and U-2 OS cells were inhibited by ZOL in both a dose- and time-dependent manner. Significant decreases in the expression of Cyclin D1, β-Catenin, and c-Myc were observed in the groups that underwent ZOL treatment. Additionally, compared to ZOL (100 μM) treatment alone, cotreatment with ZOL (100 μM) and Li2CO3 (1mM) rescued cell proliferation and restored a significant percentages of apoptotic cells. Our study suggests that the specific mechanism by which ZOL affects apoptosis of osteosarcoma cells is through the AKT/GSK-3β/β-Catenin signaling pathway. PMID: 31288526 [PubMed - as supplied by publisher]
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research